- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05116176
TRAjectories and CLinical ExpeRiences of ICD Therapy Study (TRACER-ICD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Objectives and Design
The specific aims, applicable methods, and main hypotheses of the TRACER-ICD study are as follows:
Aim 1: To characterize the clinical course of patients aged >65 after ICD implantation by establishing a multicenter prospective cohort (N=500). Baseline (verbal and in-person) and quarterly (phone, electronic health records [EHR], remote monitoring) data collected up to 18 months or death will include: a. geriatric assessments (e.g. frailty, cognition,1 functional status; b. comorbidities; c. quality of life and symptom burden; d. health services use; e. SDM history; and f. ICD-recorded physical activity (minutes/day).
Factors associated with death and poor quality of life will be identified. Group-based trajectory modeling will identify patient clusters with distinct trajectories of functional status and quality of life following ICD implantation.
H1: A model integrating frailty and clinical factors will predict (a) death, (b) poor quality of life, and (c) unfavorable functional trajectories after ICD implantation.
Aim 2: To validate a personalized prediction model of treatment outcomes of ICDs. We will apply our established semi-competing risks approach5 to the prospective cohort, enriched by the baseline geriatric assessments, to predict individual patients' probabilities of the following outcome profiles at 6, 12, and 18 months post-implant: a. death without prior shock, b. death with prior shock, c. survival without prior shock, and d. survival with prior shock. The independent contribution of frailty, cognitive dysfunction, baseline quality of life, and functional status (e.g. total deficits in ADL and IADL) to model performance will be evaluated.
H2: Addition of frailty, cognitive dysfunction, quality of life, and functional status to a model with cardiovascular variables will significantly improve model performance as assessed by area under the curve (AUC).
Aim 3: To identify optimal strategies for incorporating personalized outcome profiles into SDM. The main cohort's baseline interview and EHR review will provide quantitative data on past SDM tools used by physicians. We will develop a prototype individualized version of the Colorado SDM tool that incorporates 18-month outcome profiles using our semi-competing risk model. We will perform semi-structured interviews of cardiologists (N=20) as well as patients (N=20) recruited from the main cohort regarding process mapping of SDM from clinic to implant procedure, including timing, content, format preferences, and impressions of the prototype individualized tool.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Patients scheduled for ICD implantation will be identified at participating sites by site staff. Eligibility criteria will include the following, all of which must be met by all participants for participation:
- Patient receiving new primary prevention ICD (single, dual chamber, or subcutaneous system)
- Age >65 years
- English-speaking (N.B.: assessment instruments are only available/validated in English)
- Sufficient cognitive ability to provide consent (i.e. answer simple questions on study participation, purpose and procedures)
Description
Patients scheduled for ICD implantation will be identified at participating sites by site staff. Eligibility criteria will include the following, all of which must be met by all participants for participation:
- Patient receiving new primary prevention ICD (single, dual chamber, or subcutaneous system)
- Age >65 years
- English-speaking (assessment instruments are only available/validated in English)
- Sufficient cognitive ability to provide consent (i.e. answer simple questions on study participation, purpose and procedures)
Candidates meeting the following exclusion criteria at baseline will be excluded from study participation:
- Receipt of cardiac resynchronization therapy device
- Participation in another investigational drug or intervention trial expected to influence any of the outcomes of interest in this study
- Current drug or alcohol use or dependence that, in the opinion of the Site Principle Investigator, would interfere with adherence to study requirements.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Trajectories after ICD implantation
Time Frame: Patients will be followed quarterly for 18 months or to death.
|
Group-based trajectory modeling will identify patient clusters with distinct trajectories of functional status and quality of life following ICD implantation.
|
Patients will be followed quarterly for 18 months or to death.
|
Outcomes after ICD Implantation
Time Frame: Up to 18 months
|
Death/Poor Quality of Life (combined endpoint)
|
Up to 18 months
|
Semi-competing risks model of deaths and/or ICD shocks
Time Frame: Up to 18 months
|
Personalized outcome profiles for death +/- ICD shocks
|
Up to 18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel B Kramer, MD, MPH, Beth Israel Deaconess Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2021P000054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Implantable Defibrillator User
-
Paris Cardiovascular Research Center (Inserm U970)Hôpital Necker-Enfants MaladesCompletedImplantable Defibrillator User | Implantable Cardioverter Defibrillator Complications
-
Larisa TereshchenkoCompletedImplantable Defibrillator UserUnited States
-
Abbott Medical DevicesCompletedImplantable Defibrillator UserHungary, United States, Poland, Spain, United Kingdom
-
Biotronik, Inc.Terminated
-
Gulf Heart AssociationBoston Scientific Corporation; MedtronicCompletedImplantable Defibrillator UserUnited Arab Emirates
-
Universitätsklinikum KölnRecruitingImplantable Defibrillator User | Implantable Defibrillator Lead Dysfunction | Implantable Automatic Defibrillator MalfunctionGermany
-
Centre Hospitalier Universitaire de BesanconCompletedImplantable Defibrillator UserFrance
-
Susanne Schmidt PedersenOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDistress | Implantable Defibrillator UserDenmark
-
Biotronik, Inc.University of RochesterActive, not recruitingCardiomyopathies | Implantable Defibrillator User | GenderUnited States
Clinical Trials on Implantable cardioverter-defibrillators
-
Trialance SCCLUnknownImplantable Cardiac Device. Patients With a NMR IndicationSpain
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Arrhythmia | Death, Sudden, Cardiac | Ventricular Arrhythmia
-
Boston Scientific CorporationCompleted
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedHeart DiseasesUnited States
-
Boston Scientific CorporationCompleted
-
Population Health Research InstituteBoston Scientific CorporationCompleted
-
Medtronic Bakken Research CenterAstraZenecaCompletedAcute Myocardial InfarctionNetherlands
-
Rennes University HospitalCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedVentricular ArrhythmiasGermany, United States, Denmark, Canada, Netherlands, Switzerland, Austria
-
Paris Cardiovascular Research Center (Inserm U970)Hôpital Necker-Enfants MaladesCompletedImplantable Defibrillator User | Implantable Cardioverter Defibrillator Complications